TY  - JOUR
AU  - Mattana, Francesco
AU  - Muraglia, Lorenzo
AU  - Raiwa, Pawel
AU  - Zattoni, Fabio
AU  - Marra, Giancarlo
AU  - Chiu, Peter K F
AU  - Heidegger, Isabel
AU  - Kasivisvanathan, Veeru
AU  - Kesch, Claudia V
AU  - Olivier, Jonathan
AU  - Preisser, Felix
AU  - Thibault, Constance
AU  - Valerio, Massimo
AU  - van den Bergh, Roderick C N
AU  - Gandaglia, Giorgio
AU  - Ceci, Francesco
TI  - Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
JO  - European urology oncology
VL  - 6
IS  - 2
SN  - 2588-9311
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2023-00377
SP  - 128-136
PY  - 2023
N1  - 2023 Apr;6(2):128-136
AB  - The introduction of prostate-specific membrane antigen positron emission tomography (PSMA-PET) had a substantial impact on the management of prostate cancer (PCa) patients with a stage migration phenomenon and consequent treatment changes.To summarise the role of PSMA-PET to define the burden of disease through an accurate location of metastatic site(s) in PCa patients, describing the most common locations at PSMA-PET in the primary staging and recurrence setting, and to assess the clinical impact in the decision-making process.A comprehensive nonsystematic literature review was performed in April 2022. Literature search was updated until March 2022. The most relevant studies have been summarised, giving priority to registered clinical trials and multicentre collaborations.PSMA-PET showed higher diagnostic accuracy than conventional imaging both in newly diagnosed PCa and in recurrent disease. This greater accuracy led to a migration of a higher proportion of patients identified with metastatic disease. Bone metastases were reported as the most frequent site of metastatic spread in staging (up to 17
KW  - Biochemical recurrence (Other)
KW  - Metastatic prostate cancer (Other)
KW  - Positron emission tomography (Other)
KW  - Prostate-specific membrane antigen (Other)
KW  - Prostate-specific membrane antigen prostate cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36804735
DO  - DOI:10.1016/j.euo.2023.01.014
UR  - https://inrepo02.dkfz.de/record/271245
ER  -